OEL Fastrac Catalog

O-Methylbufotenine (also known as 5-MeO-DMT) is a tryptamine alkaloid that is N,Ndimethyltryptamine substituted by a methoxy group at position 5. It has a role as a hallucinogen and a plant metabolite. It is a tryptamine alkaloid, an aromatic ether and a tertiary amino compound. It derives from a bufotenin. O-Methylbufotenine (also known as 5-MeO-DMT) was initially isolated from the bark of Dictyoloma incanescens D.C. It is a major active ingredient of South American Virola snuffs and ayahuasca beverage. 5-MeODMT also represents the active constituent of the venom of Colorado River Bufo alvarius toads, and it accounts for 15% of the dry weight of the toads’ parotoid and tibial glands. In addition, 5-MeO-DMT may be synthesized in human pineal and retina and has been identified in human body fluids including urine, blood, and cerebrospinal fluid. 5-MeO-DMT is regarded as an endogenous psychotoxin, and elevated concentrations of 5-MeO-DMT and its analogs in body fluids might be associated with psychotic disorders such as schizophrenic psychosis.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Please note: Due to the complexity and amount of studies regarding this compound—a Natural Health Product—increased cost is charged.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for O-Methylbufotenine, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.